Iomeron (Iomeprol)

Iomeprol contains iodine atoms with a high atomic number, which absorb X‑ray photons more efficiently than surrounding tissues. When the solution is administered, the iodine distributes in the targeted area, raising X‑ray attenuation and creating a pronounced contrast between the area of interest and adjacent structures, thereby enhancing image quality.

The dose of Iomeron is individualized by the prescribing physician based on the specific imaging study, patient size, renal function and the route of administration. Healthcare professionals calculate the appropriate volume and concentration to achieve optimal contrast while minimizing risk.

Safety data for Iomeron in pregnancy and lactation are limited. It should only be used when clearly needed and when the potential diagnostic benefit outweighs any possible risk to the fetus or infant. The prescribing clinician must evaluate each case and discuss potential risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Iomeron. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Iomeron (iomeprol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. It provides high image quality while reducing the incidence of discomfort and adverse reactions, making it a preferred choice for many vascular, joint and spinal imaging procedures.

Iomeron should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture and extreme temperatures. Do not freeze or shake the vial before use; inspect for particulate matter or discoloration prior to administration.

Iomeron is supplied as a sterile solution for injection and is administered by a qualified healthcare professional via intra‑arterial, intra‑articular or intrathecal routes, depending on the imaging study. The injection is performed under aseptic conditions, and the volume is adjusted to the specific diagnostic requirement.

Serious risks, although rare, include anaphylactic or severe allergic reactions, acute kidney injury, marked hypotension and cardiac arrhythmias. Patients with known iodine allergy, severe renal impairment or uncontrolled thyroid disease should be closely monitored, and emergency measures must be readily available during administration.

Iomeron is contraindicated in patients with a documented severe allergy to iodine‑based contrast agents, those with uncontrolled hyperthyroidism, and individuals with a history of severe renal failure where alternative imaging methods are feasible. The prescribing clinician must assess each patient’s medical history before use.